Monday, 9 Nov 2026

Empowering Chinese Pharma’s Global Expansion

Contact US
Insight,  China's Pharmaceutical Industry
  • Home
  • About US
  • Policy Hub
  • Categories
    • Drug
    • Company
    • Deals
    • Policy / Regulatory
    • Medical Device
    • R&D
    • Legal / IP
    • Digital
  • Privacy Policy
  • Contact US
My News
  • Cancer
  • Clinical trial approval / initiation
  • Product approvals
  • Clinical trial results
  • Finance
  • ADC / XDC
  • Finanical Reports
  • Biotech
  • Market approval filings
  • PD-1/L1
Insight,  China's Pharmaceutical IndustryInsight,  China's Pharmaceutical Industry
  • Read History
Search
  • Pages
    • Home
    • Blog Index
    • POLICY HUB
    • Contact Us
  • Personalized
    • Read History
  • Categories
    • Company
    • Drug
    • Policy / Regulatory
    • Medical Device
    • R&D
    • Digital
    • Legal / IP
    • Deals
Have an existing account? Sign In
Follow US

NASDAQ: ONVO

  • #
  • Cancer
  • Clinical trial approval / initiation
  • Product approvals
  • Clinical trial results
  • Finance
  • ADC / XDC
  • Finanical Reports
  • Biotech
  • Market approval filings
  • PD-1/L1
  • Rare / orphan disease drugs
  • Auto-immune
  • Vaccine
  • Cell-therapy
  • Multi-specific antibodies
  • CVD
  • AstraZeneca
  • Hengrui Pharmaceuticals
  • Diabetes
  • SHA: 600276
RonGu Biotechnology Completes Series A Financing of Nearly RMB 100 Million – Advancing Off‑the‑Shelf CAR‑NK and CAR‑T Therapies for Systemic Lupus Erythematosus
CompanyDeals

RonGu Biotechnology Completes Series A Financing of Nearly RMB 100 Million – Advancing Off‑the‑Shelf CAR‑NK and CAR‑T Therapies for Systemic Lupus Erythematosus

Hangzhou RonGu Biotechnology Co., Ltd. ("RonGu Biotechnology") announced the completion of a Series A financing of nearly RMB 100 million. The round was jointly participated by Changjin Holdings, Yichen Investment,…

November 9, 2026
Eisai and Siemens Healthineers Sign Strategic Cooperation Agreement at CIIE – Advancing Precision Imaging in Alzheimer's Disease Diagnosis and Treatment

Eisai and Siemens Healthineers Sign Strategic Cooperation Agreement at CIIE – Advancing Precision Imaging in Alzheimer’s Disease Diagnosis and Treatment

November 9, 2026
Sanyou Biopharmaceuticals Completes Series C Financing of Nearly RMB 100 Million – Zero2IPO Industry Investment Fund Backs AI‑Driven Drug Discovery Platform

Sanyou Biopharmaceuticals Completes Series C Financing of Nearly RMB 100 Million – Zero2IPO Industry Investment Fund Backs AI‑Driven Drug Discovery Platform

November 9, 2026

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
Eli Lilly Acquires Organovo's FXR Program for Inflammatory Bowel Disease
CompanyDeals

Eli Lilly Acquires Organovo’s FXR Program for Inflammatory Bowel Disease

February 26, 2025
Insight,  China's Pharmaceutical Industry

Information You Can Trust: Stay instantly connected with breaking stories and live updates. From politics and technology to entertainment and beyond, we provide real-time coverage you can rely on, making us your dependable source for 24/7 news.

Youtube Medium Rss

About Company

  • Contact Us
  • Advertise with US
  • Complaint
  • Our Team
  • Our Values
  • Privacy Policy
Subscribe Now for Real-time Updates on the Latest Stories!

© 2026 Fineline Information & Technology. Independent intelligence on China’s pharmaceutical industry.  All Rights Reserved.

Fineline Information & Technology
Welcome to Fineline Cube!
Username or Email Address
Password

Lost your password?

Not a member? Sign Up